Holen Sie sich die Stockscreener-App
1.51
2.25%
-0.04
Schlusskurs vom Vortag:
$1.55
Offen:
$1.57
24-Stunden-Volumen:
430.89K
Relative Volume:
0.34
Marktkapitalisierung:
$33.02M
Einnahmen:
$752.00K
Nettoeinkommen (Verlust:
$-68.21M
KGV:
-0.1557
EPS:
-9.6977
Netto-Cashflow:
$-58.21M
1W Leistung:
+2.37%
1M Leistung:
-4.11%
6M Leistung:
-51.28%
1J Leistung:
-32.51%
1-Tages-Spanne:
$1.495
$1.615
1-Wochen-Bereich:
$1.44
$1.7983
52-Wochen-Spanne:
$1.17
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Firmenname
Bioxcel Therapeutics Inc
Sektor
Telefon
203-643-8060
Adresse
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.51 | 33.90M | 752.00K | -68.21M | -58.21M | -9.6977 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
114.58 | 48.74B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.03 | 44.85B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.67 | 34.12B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
540.33 | 23.35B | 3.13B | 1.27B | 1.12B | 26.39 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-21 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-07-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-03-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-01 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-06 | Bestätigt | BofA Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-02-01 | Eingeleitet | UBS | Buy |
| 2020-10-30 | Eingeleitet | Goldman | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-04 | Eingeleitet | Guggenheim | Buy |
| 2020-04-01 | Eingeleitet | BofA/Merrill | Buy |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
Alle ansehen
Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten
BioXcel Therapeutics closes $8M registered direct offering - Investing.com Australia
How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding Needs - Yahoo Finance
BioXcel Therapeutics raises $8M in stock offering - Hartford Business Journal
BioXcel Therapeutics Announces Registered Direct Offering and Warrant Amendment – SEC 8-K Filing March 2026 - Minichart
BioXcel Therapeutics Announces Registered Direct Equity Financing - TipRanks
BioXcel Therapeutics, Inc. Completes $8 Million Registered Direct Offering of Common Stock and Warrants - Quiver Quantitative
BioXcel Therapeutics Closes $8.0 Million Direct Offering - marketscreener.com
AI-driven drugmaker BioXcel raises $8M, extends investor warrants - Stock Titan
BioXcel Therapeutics raises $8M in registered direct offering - Investing.com Australia
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering - Bitget
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering - GlobeNewswire Inc.
BioXcel Therapeutics raises $8M in registered direct offering By Investing.com - Investing.com Nigeria
Aug Technicals: Is BioXcel Therapeutics Inc benefiting from interest rate changesQuarterly Risk Review & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Why Are BioXcel Therapeutics Shares Down Friday? - Benzinga
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal - Sahm
BioXcel Therapeutics Seeks Market Expansion amid Financial Struggles - timothysykes.com
BioXcel Therapeutics Stock Soars Amid New Drug Approval Speculation - StocksToTrade
BTAI Stock Gained 5% TodayWhat's The Latest On Its Opioid Withdrawal Treatment? - Stocktwits
BioXcel Therapeutics (BTAI) Target Price Lowered by HC Wainwrigh - GuruFocus
BioXcel Therapeutics shares rise 2.7% as experimental opioid withdrawal drug shows benefit in mid-stage trial - marketscreener.com
BioXcel Therapeutics Achieves Milestone with Igalmi’s Market Study - timothysykes.com
BioXcel Therapeutics Stock Rallies Opioid Study Success - Benzinga
Why Did BTAI Stock Surge 20% In Pre-Market Today? - Asianet Newsable
BioXcel Therapeutics (BTAI) Reports Promising Phase 2 Results fo - GuruFocus
BTAI Stock Surges Pre-Market After On Positive Trial Results For Opioid Withdrawal Treatment - Stocktwits
BioXcel Therapeutics shares rise 21.1% premarket as experimental opioid withdrawal drug shows benefit in mid-stage trial - marketscreener.com
BioXcel Therapeutics rises amid sector rotation - Intellectia AI
Bioxcel Therapeutics announces positive Phase 2 topline results from Columbia University-led study of BXCL501 for treatment of opioid withdrawal - marketscreener.com
BioXcel reports positive Phase 2 data for opioid withdrawal drug By Investing.com - Investing.com UK
Bioxcel Therapeutics Announces Positive Phase 2 Topline Results From Columbia University-Led Study Of BXCL501 For Treatment Of Opioid Withdrawal - TradingView
BioXcel Therapeutics Announces Positive Phase 2 Topline - GlobeNewswire
BTAI PE Ratio & Valuation, Is BTAI Overvalued - Intellectia AI
BTAI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AI Drugmaker BioXcel Eyes $9.8M Investor Settlement - Law360
BTAI SEC FilingsBioxcel Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BioXcel Submits sNDA for Igalmi to Treat Agitation - Intellectia AI
Is BioXcel Therapeutics Inc. stock good for income investorsJuly 2025 Rallies & Risk Controlled Stock Alerts - mfd.ru
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia - Bitget
BioXcel Therapeutics (BTAI) Hosts Roundtable on Acute Agitation in Alzheimer's - GuruFocus
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia - The Manila Times
Doctors tackle 100M Alzheimer’s agitation episodes in new BioXcel webcast - Stock Titan
BioXcel Therapeutics to Host Virtual Roundtable Featuring - GlobeNewswire
Why BioXcel Therapeutics Inc. stock is favored by pension fundsJuly 2025 Macro Moves & Advanced Technical Analysis Signals - mfd.ru
Aug Weekly: Is BioXcel Therapeutics Inc gaining market shareTrade Exit Report & Safe Swing Trade Setups - baoquankhu1.vn
BioXcel Therapeutics Reports Successful Primary Endpoint Achievement in SERENITY At-Home Phase 3 Safety Trial, Supporting sNDA for IGALMI® Label Expansion - Intellectia AI
Can BioXcel Therapeutics Inc. stock hit record highs againBond Market & Weekly Breakout Opportunity Watchlist - mfd.ru
BTAI Should I Buy - Intellectia AI
What earnings margins imply for BioXcel Therapeutics Inc. (BX20) stockJuly 2025 Levels & Daily Momentum Trading Reports - mfd.ru
Movement Recap: Is BioXcel Therapeutics Inc. benefiting from interest rate changes2025 Top Decliners & AI Driven Stock Movement Reports - mfd.ru
Bioxcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for Igalmi in the At-Home Setting - marketscreener.com
BioXcel Therapeutics (BTAI) Advances with Igalmi for At-Home Use - GuruFocus
Finanzdaten der Bioxcel Therapeutics Inc-Aktie (BTAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.26%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):